CGRP antagonists for decreasing migraine frequency: New options, long overdue

Cleve Clin J Med. 2020 Apr;87(4):211-218. doi: 10.3949/ccjm.87a.19048.

Abstract

The cornerstone of preventive migraine treatment has long been drugs developed for other diseases such as epilepsy, depression, and hypertension. But a new set of drugs is available for preventing migraine attacks: erenumab, galcanezumab, fremanezumab, and eptinezumab. These monoclonal antibodies target calcitonin gene-related peptide (CGRP) or its receptors, each a key molecule in the pathophysiology of migraine.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors*
  • Calcitonin Gene-Related Peptide / therapeutic use*
  • Humans
  • Migraine Disorders / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • fremanezumab
  • galcanezumab
  • eptinezumab
  • erenumab
  • Calcitonin Gene-Related Peptide